April 20, 2021
6 minutes of reading
This story originally appeared on Stock market
Are these the best healthcare stocks to buy right now?
Healthcare stocks are among the most important in the industry stock market right now, if not the most. With the devastation of the epidemic, the focus on health care has intensified even more. These include companies that sell medical supplies, provide medical services or even provide real estate to medical organizations. They may come from vaccine companies like Moderna Inc (NASDAQ: MRNA) or even gene therapy companies Celcuity Inc (NASDAQ: CELC) can bring about significant changes to the world.
Take for example Moderna, one of the pioneers in the production of the COVID-19 vaccine. This has brought in huge profits for the company since the pandemic began. As a result, the company’s share price tripled in value over the past year. Furthermore, the company recently highlighted the release of antibody survival data for 6 months after the second dose of the Moderna COVID-19 vaccine.
To date, COVID-19 has claimed the lives of about 3 million people globally. However, there are still other diseases that continue to plague humanity, some of which are still on the radar from time to time. Other healthcare companies are working on treatments for a variety of diseases, and investors are aware of this as well. With that said, let’s take a look at four Top healthcare stocks on today’s stock market.
Healthcare stocks to buy [Or Sell] Right now
Beam Therapeutics Inc
First of all, we have ray treatments. This is a biotechnology company that focuses on precise genetic drugs based on its basic editing technology. The basic editors allow for exactly one letter of the gene to be rewritten. This could lead to lifelong cures for serious illnesses. Its most advanced preclinical candidate, BEAM-101, for example, targets the treatment of rare blood diseases beta-thalassemia and sickle cell disease. As some of you may know, the company does not yet have any programs in clinical trials. The aforementioned candidate is expected to be approved by the US Food and Drug Administration (FDA) later this year for an early stage clinical trial. With such exciting technology, will Beam have the potential to make the next big breakthrough in genetic medicine?
Despite the lack of any clinical trial program, the company’s stock price has risen more than 300% in the past year. In February, Beam acquired GuideTx, a developer of non-viral drug transport vehicles for genetic drugs. GuideTx’s technology is capable of allowing much faster sieving times by sifting through hundreds of nanoparticles in a single experiment.
As of December 31, 2020, the company has $ 299.7 million in cash. This was further reinforced in January 2021 when the company raised a total of $ 260 million from a private placement. Beam’s strong cash position will likely be enough to fund the company’s clinical development over the next few years. In March 2021, Beam appointed Amy Simon, MD, as chief medical officer. Dr. Simon brings over 20 years of clinical experience to Beam. Given all this development, would you consider buying BEAM stock?
Issued Medical Inc
Next, we have Editas Medicine. It is a leading genomic editing company focused on translating the potential of CRISPR gene editing to develop a powerful drug system. Currently, the company is focusing on three main areas of treatment: eye diseases, cancer and blood diseases.
Shares are up nearly 50% year-on-year. Also, earlier this year, EDIT shares hit an all-time high of $ 99.95. However, the stock has fallen more than 60% since then. That may be due to skepticism surrounding the initial results from the company’s EDIT-101 experimental gene editing product CRISPR. Some people may know that this is the first time to manage one in vivo Gene editing medicine in humans. Considering the novelty of the product, it is not surprising that some observers are not interested in it.
Financially, the company saw its revenue quadruple in the fiscal year December 31, 2021. Additionally, the company’s net loss fell 13% to $ 116 million. In February 2021, Editas announced the appointment of James C. Mullen as CEO. He has extensive industry experience, including experience as the CEO of giant biotech conglomerate Biogen (NASDAQ: BIIB), possibly a good omen for Editas. Considering all this, are you willing to spend the opportunity to buy EDIT stock?
Visual Surgery, Inc.
Surgical Visualization is a company that develops, manufactures and markets robotic products designed to improve patient clinical outcomes. This is achieved through minimally invasive surgery, most notably with the Ion System and da Vinci Surgery. This will make the surgeries more effective, less invasive and easier for the surgeon as well as the patient.
The company’s market share has increased by more than 50% in the past year. The positive sentiment surrounding the company’s stock could be a result of its dominance in the robot-assisted surgical space. Specifically, by the end of 2020, the company has installed nearly 6,000 surgical systems worldwide. What’s more, it’s worth noting that none of its competitors have come close to what visual surgery has achieved so far.
Despite the impact of the pandemic, Visual Surgery is still able to make a profit in the fourth quarter of 2020 results. Fourth quarter 2020 revenue is $ 1.33 billion, up 4% year-on-year. Meanwhile, net income for the quarter was $ 365 million, up 2% from a year ago. It is worth mentioning that the company actually shipped fewer systems during the quarter. However, the growth in da Vinci procedure volume more than makes up for it. The potential for robotic-assisted surgical devices remains enormous, and Intuitive Surgery is at the forefront of that wave of innovation. With that in mind, are you planning to invest in ISRG stocks?
Veeva Systems Inc
Finally on the list, we have Veeva Systems. The company provides cloud solutions for the global life sciences industry. Its solution allows companies to realize the benefits of modern cloud-based architecture and mobile applications for their business functions. In short, it helps companies get products to market faster and more efficiently. As a result, the company’s share price has increased by almost 50% over the past year.
In a world where technology and healthcare are trending, the company’s performance isn’t surprising. On April 15, leading clinical research company and organization Parexel announced a strategic partnership. This partnership involves Parexel standardizing Veeva’s clinical suite of action to streamline operations. In addition, Parexel will soon access and provide input to Veeva’s clinical products.
“Together, we can accelerate the way our customers bring new vaccines, diagnoses, equipment, and therapies to patients in need.”Said Peter Gassner, Founder and CEO of Veeva. In a world where technology is playing a bigger role in health care, this presents an amazing opportunity for Veeva. With a long growth road ahead, would you consider adding VEEV stock to your portfolio?